Scarica l'app Stockscreener
314.40
1.92%
5.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Is Alnylam Pharmaceuticals (ALNY) one of the best upside stocks to invest in right now? - MSN
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? - Finviz
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback? - simplywall.st
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations (ALNY) - Seeking Alpha
RBC Capital lowers Alnylam Pharmaceuticals stock price target on short-term headwinds - Investing.com Canada
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down - TradingView
Demystifying Alnylam Pharmaceuticals: Insights From 13 Analyst Reviews - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript - Insider Monkey
RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating - marketscreener.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital - MarketBeat
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) ROE Of 19% Impressive? - Yahoo Finance
Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
RNA Therapeutics Market Set to Boom: Strategic Insights - openPR.com
Why Alnylam Pharmaceuticals Stock Slipped Today - The Globe and Mail
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus
Alnylam turns a profit for first time in 24-year history - The Business Journals
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q4 2025 Earnings Conference - 富途牛牛
Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlig - GuruFocus
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Swing To Profit On Strong 2025 Earnings - simplywall.st
ALNY: Needham Maintains Buy Rating with Lowered Price Target | A - GuruFocus
Needham & Company LLC Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast - Investing.com Nigeria
Alnylam Pharmaceuticals (ALNY) Projects Significant Revenue Grow - GuruFocus
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast By Investing.com - Investing.com India
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance - FinancialContent
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings - Yahoo! Finance Canada
Alnylam Pharmaceuticals (ALNY) Q4 Earnings Miss Estimates - GuruFocus
Alnylam: Q4 Earnings Snapshot - kens5.com
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates - Yahoo Finance
Alnylam: Fourth Quarter Financial Highlights - Bitget
ALNYLAM PHARMACEUTICALS ($ALNY) Releases Q4 2025 Earnings - Quiver Quantitative
Alnylam Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Issues 2026 Outlook - marketscreener.com
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $1.25 per Share - marketscreener.com
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B - marketscreener.com
ALNYLAM PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress - Yahoo Finance
Krilogy Financial LLC Acquires New Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc impacted by rising ratesPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
Alnylam earnings ahead: Can blockbuster TTR drug deliver? By Investing.com - Investing.com Canada
Will Alnylam Pharmaceuticals Inc. stock return to pre crisis levels2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - mfd.ru
Envestnet Asset Management Inc. Has $54.25 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Have A Healthy Balance Sheet? - Yahoo Finance
Candriam S.C.A. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026? - TIKR.com
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Unpacking A 46.21% Potential Upside - DirectorsTalk Interviews
Do options traders know something about Alnylam Pharmaceuticals stock we don't? - MSN
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - MSN
Insider Trends: Should value investors consider Alnylam Pharmaceuticals Inc2025 AllTime Highs & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? - Finviz
Allianz Asset Management GmbH Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Hantz Financial Services Inc. - MarketBeat
Alnylam Pharmaceuticals (ALNY) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 49% Undervaluation? - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Revenue Outlook And Long Term Growth Targets - simplywall.st
Alnylam Pharmaceuticals (BIT:1ALNY) Price Target Decreased by 11.40% to 411.81 - Nasdaq
Alnylam Pharmaceuticals (ALNY): Investor Outlook with a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd - MarketBeat
0.10%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):